Literature DB >> 23124271

mTOR signaling in neural stem cells: from basic biology to disease.

Laura Magri1, Rossella Galli.   

Abstract

The mammalian target of rapamycin (mTOR) pathway is a central controller of growth and homeostasis, and, as such, is implicated in disease states where growth is deregulated, namely cancer, metabolic diseases, and hamartoma syndromes like tuberous sclerosis complex (TSC). Accordingly, mTOR is also a pivotal regulator of the homeostasis of several distinct stem cell pools in which it finely tunes the balance between stem cell self-renewal and differentiation. mTOR hyperactivation in neural stem cells (NSCs) has been etiologically linked to the development of TSC-associated neurological lesions, such as brain hamartomas and benign tumors. Animal models generated by deletion of mTOR upstream regulators in different types of NSCs reproduce faithfully some of the TSC neurological alterations. Thus, mTOR dysregulation in NSCs seems to be responsible for the derangement of their homeostasis, thus leading to TSC development. Here we review recent advances in the molecular dissection of the mTOR cascade, its involvement in the maintenance of stem cell compartments, and in particular the implications of mTOR hyperactivation in NSCs in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124271     DOI: 10.1007/s00018-012-1196-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  112 in total

1.  Biallelic TSC gene inactivation in tuberous sclerosis complex.

Authors:  Peter B Crino; Eleonora Aronica; Gordon Baltuch; Katherine L Nathanson
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

2.  Mosaic organization of neural stem cells in the adult brain.

Authors:  Florian T Merkle; Zaman Mirzadeh; Arturo Alvarez-Buylla
Journal:  Science       Date:  2007-07-05       Impact factor: 47.728

3.  Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism.

Authors:  K Hara; K Yonezawa; Q P Weng; M T Kozlowski; C Belham; J Avruch
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

4.  Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Nicholas R Rensing; Bo Zhang; David H Gutmann; Michael J Gambello; Michael Wong
Journal:  Hum Mol Genet       Date:  2010-11-09       Impact factor: 6.150

5.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

6.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

7.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

Authors:  James B Brugarolas; Francisca Vazquez; Archana Reddy; William R Sellers; William G Kaelin
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

8.  mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells.

Authors:  Jiaxi Zhou; Pei Su; Lu Wang; Joanna Chen; Maike Zimmermann; Olga Genbacev; Olubunmi Afonja; Mary C Horne; Tetsuya Tanaka; Enkui Duan; Susan J Fisher; Jiayu Liao; Jie Chen; Fei Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-28       Impact factor: 11.205

Review 9.  The glial nature of embryonic and adult neural stem cells.

Authors:  Arnold Kriegstein; Arturo Alvarez-Buylla
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

Review 10.  Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis.

Authors:  Nicole A Neuman; Elizabeth Petri Henske
Journal:  EMBO Mol Med       Date:  2011-03-16       Impact factor: 12.137

View more
  17 in total

1.  Quantitative analysis of male germline stem cell differentiation reveals a role for the p53-mTORC1 pathway in spermatogonial maintenance.

Authors:  Mulin Xiong; Ianina C Ferder; Yasuyo Ohguchi; Ning Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  New frontiers in modeling tuberous sclerosis with human stem cell-derived neurons and brain organoids.

Authors:  John D Blair; Helen S Bateup
Journal:  Dev Dyn       Date:  2019-05-23       Impact factor: 3.780

Review 3.  Regenerating optic pathways from the eye to the brain.

Authors:  Bireswar Laha; Ben K Stafford; Andrew D Huberman
Journal:  Science       Date:  2017-06-09       Impact factor: 47.728

4.  Hamartin regulates cessation of mouse nephrogenesis independently of Mtor.

Authors:  Oded Volovelsky; Thi Nguyen; Alison E Jarmas; Alexander N Combes; Sean B Wilson; Melissa H Little; David P Witte; Eric W Brunskill; Raphael Kopan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-21       Impact factor: 11.205

5.  Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2.

Authors:  Polina Kosillo; Kamran M Ahmed; Erin E Aisenberg; Vasiliki Karalis; Bradley M Roberts; Stephanie J Cragg; Helen S Bateup
Journal:  Elife       Date:  2022-07-26       Impact factor: 8.713

6.  Glucocorticoid receptors in the retina, Müller glia and the formation of Müller glia-derived progenitors.

Authors:  Donika Gallina; Christopher Zelinka; Andy J Fischer
Journal:  Development       Date:  2014-08-01       Impact factor: 6.868

7.  Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.

Authors:  Paola Zordan; Manuela Cominelli; Federica Cascino; Elisa Tratta; Pietro L Poliani; Rossella Galli
Journal:  J Clin Invest       Date:  2018-03-12       Impact factor: 14.808

Review 8.  Current Approaches and Future Directions for the Treatment of mTORopathies.

Authors:  Vasiliki Karalis; Helen S Bateup
Journal:  Dev Neurosci       Date:  2021-04-28       Impact factor: 2.984

9.  Intrahippocampal glutamine administration inhibits mTORC1 signaling and impairs long-term memory.

Authors:  Natalia S Rozas; John B Redell; Juan D Pita-Almenar; James Mckenna; Anthony N Moore; Michael J Gambello; Pramod K Dash
Journal:  Learn Mem       Date:  2015-04-15       Impact factor: 2.460

Review 10.  Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation.

Authors:  Candi L Lasarge; Steve C Danzer
Journal:  Front Mol Neurosci       Date:  2014-03-14       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.